The Research Triangle Park, N.C.-based company said it expects to post sales of $5.4 million, just in line with the consensus on Wall Street.
TransEnterix said that its revenue mainly came through the sale of four Senhance systems. The company said it sold one system to UPMC to be used in Pittsburgh’s Magee-Womens Hospital, and three systems in the EMEA region, two of which went to distributors while the last was sold to Veldhoven, the Netherlands’ Maxima Medical Center.
The company said it currently has approximately $82 million on the balance sheet, which it expects will fund its business through to 2020.
“We made significant progress during the third quarter, including the continued adoption of Senhance, driven by the advancement of our sales and marketing strategy, the announcement of the MST acquisition agreement and the expansion of our instrument portfolio. As we look towards the remainder of 2018 and into 2019, we are focused on increasing the applicability of Senhance to more patients, surgeons, and hospitals and growing on a global basis,” prez & CEO Todd Pope said in a prepared statement.
Shares jumped from an opening price of $5.75 to $6.01 the day after the news was released, Today, shares are trending slightly down, at $5.96 as of 9:40 a.m. EDT.
Earlier this week, TransEnterix said that it won CE Mark approval in the European Union for the Senhance Ultrasonic instrument system, designed to operate with its Senhance robot-assisted surgery device.